Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 August 2023 | Story Anthony Mthembu | Photo Supplied
Ndumiso Mbuthuma
Ndumiso Mbuthuma is currently pursuing a PhD in Development Studies with a focus on floods and disasters.

Ndumiso Mbuthuma, a PhD student at the University of the Free State (UFS), was part of a team that won the Durban leg of the Students Reinventing Cities competition. “It was a beautiful experience and an opportunity to not only be a student again but to contribute to the greater good,” Mbuthuma said.

The Students Reinventing Cities competition is coordinated by C40, a global network of nearly 100 mayors of the world’s leading cities who are united in action to confront the climate crisis.

The Umgeni Interchange Team, which consisted of Mbuthuma, who is a student in the UFS Centre for Development Support, three students from the University of Cape Town, and one from an institution in France, participated in the Durban leg of the competition, which began in April 2023. 

After deliberations by C40 and city representatives, the team was informed on 13 July 2023 that they had been selected as the winners of the regional Durban competition.

The Students Reinventing Cities competition provides a platform for students and academics to work with cities around the world to formulate plans to combat climate change. This year the competition took place in 12 cities, including Barcelona, Durban, Rome, Melbourne, and Milan, among others. “The aim of the competition is to find ways in which we can begin to build cities that are climate change-friendly,” Mbuthuma said. 

The winning presentation

The Umgeni Interchange Team was allocated four hectares of land by the eThekwini municipality to come up with a development idea. The team members, who specialise in various fields, had to rely on each other to create a winning project. Their proposal entailed the development of a mixed-use, commercial, retail, and affordable-housing block. 

“We wanted to ensure affordable housing not just for the rich but even for those who aren’t,” Mbuthuma explained. His PhD, which focuses on floods and disasters, provided guidance on ensuring that the housing block was resistant to floods and other disasters. The proposal also suggested sustainable resource use, including the use of solar panels to generate energy in order to reduce the impact of loadshedding. 

Even though a victory in the competition is a great feeling, Mbuthuma is more appreciative of the opportunity to have been active in the battle for a more sustainable future. “To hear that policymakers are interested in hearing what I have to say is a big deal to me.”

Future endeavours

Although there has been a concerted effort globally to combat climate change, Mbuthuma believes that in countries such as South Africa there hasn’t been adequate discourse around how development will take place in a future defined by climate change and the resulting disasters expected. As such, he is committed to working towards normalising these conversations.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept